ProCE Banner Activity

ARROW: Phase I Trial of BLU-667, a Novel RET Inhibitor, in Patients With Advanced RET Fusion–Positive NSCLC

Slideset Download
Conference Coverage
BLU-667, a selective and potent RET inhibitor, achieved a high response rate with durable responses in patients with RET+ NSCLC regardless of prior treatment.

Released: June 04, 2019

Expiration: June 02, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro